公司于2026年2月25日召开第六届董事会第十次会议，审议通过了《关于补选独立董事及调整董事会专 门委员会委员的议案》，董事会同意提名宋金波先生为公司第六届董事会独立董事候选人，任期自公司 2026年第一次临时股东会审议通过之日起至第六届董事会任期届满之日止。经股东会审议通过后，宋金 波先生将同时担任公司第六届董事会薪酬与考核委员会召集人、战略委员会委员及审计委员会委员职 务。 格隆汇2月25日丨凯因科技（维权）(688687.SH)公布，北京凯因科技股份有限公司于近日收到独立董事 杜臣先生的辞职报告，杜臣先生因连续担任公司独立董事将满六年，申请辞去公司第六届董事会独立董 事、董事会薪酬与考核委员会召集人、战略委员会委员及审计委员会委员职务，辞职后不再担任公司任 何职务。 ...

格隆汇2月25日丨凯因科技(688687.SH)公布，北京凯因科技股份有限公司于近日收到独立董事杜臣先生 的辞职报告，杜臣先生因连续担任公司独立董事将满六年，申请辞去公司第六届董事会独立董事、董事 会薪酬与考核委员会召集人、战略委员会委员及审计委员会委员职务，辞职后不再担任公司任何职务。 公司于2026年2月25日召开第六届董事会第十次会议，审议通过了《关于补选独立董事及调整董事会专 门委员会委员的议案》，董事会同意提名宋金波先生为公司第六届董事会独立董事候选人，任期自公司 2026年第一次临时股东会审议通过之日起至第六届董事会任期届满之日止。经股东会审议通过后，宋金 波先生将同时担任公司第六届董事会薪酬与考核委员会召集人、战略委员会委员及审计委员会委员职 务。 ...

凯因科技公告称，2026年2月25日公司召开会议，同意与先为达生物签订《〈技术转让（技术秘密）合 同〉之补充协议》。2019年5月，公司与先为达生物签署技术转让合同，转让GLP - 1相关药物技术秘 密。补充协议明确了标的产品（埃诺格鲁肽片等）未来浮动收益分成，若采用重组表达工艺，分成比例 为5%；若采用化学合成工艺，分成比例为2.5%。既有安排下，公司可获XW003所得收入的5%，本次签 署对财务和经营无重大不利影响，但未来收益存在不确定性。 ...

Group 1 - The core point of the article is that Kaiyin Technology reported a total of 14,429 shareholders as of February 10, 2026 [2]

Group 1 - The core point of the article is that Kaiyin Technology reported a total of 14,707 shareholders as of January 30, 2026 [1]

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between 26 million and 38 million yuan, representing a decrease of 10.43692 million to 11.63692 million yuan compared to the previous year, which is a year-on-year decline of 73.31% to 81.74% [1] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 20 million and 30 million yuan, a decrease of 10.69831 million to 11.69831 million yuan compared to the previous year, reflecting a year-on-year decline of 78.10% to 85.40% [1] - The previous year's net profit attributable to shareholders of the parent company was 142.3692 million yuan, with a total profit of 176.8329 million yuan for 2024 [1][2] Group 2 - The primary reason for the significant change in performance is the company's decision to fully provision for asset impairment related to the withdrawal of a drug registration application for a new hepatitis indication, which was based on the latest review recommendations from the National Medical Products Administration [3] - Excluding the impact of this asset impairment, the company's net profit for 2025 is expected to be roughly in line with the previous year, indicating stable development of its core business [3]

Group 1 - The company, Kaiyin Technology, announced an expected net profit attributable to shareholders of the parent company for the year 2025 to be between 26 million and 38 million yuan [1] - This represents a decrease of 104.3692 million to 116.3692 million yuan compared to the same period last year [1] - The year-on-year decline is projected to be between 73.31% and 81.74% [1]

Core Viewpoint - Kaiyin Technology (688687.SH) forecasts a significant decline in net profit for the fiscal year 2025, projecting a net profit attributable to shareholders of the parent company between 26 million to 38 million yuan, indicating a substantial decrease compared to the previous year [1] Financial Performance - The expected net profit for 2025 represents a decrease of 104.3692 million to 116.3692 million yuan compared to the same period last year [1] - This translates to a year-on-year decline of approximately 73.31% to 81.74% [1]

Group 1 - The company, Kaiyin Technology (688687.SH), has released a performance forecast for the year 2025, expecting a net profit attributable to shareholders of the parent company to be between 26 million and 38 million yuan [1] - This represents a decrease of 104.3692 million to 116.3692 million yuan compared to the same period last year, indicating a year-on-year decline of 73.31% to 81.74% [1]

Core Viewpoint - The company, Kaiyin Technology (688687.SH), expects a significant decline in net profit for the year 2025, primarily due to substantial asset impairment provisions [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company between 26 million to 38 million yuan, representing a year-on-year decrease of 73.31% to 81.74% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 20 million to 30 million yuan, reflecting a year-on-year decline of 78.10% to 85.40% [1] Reasons for Performance Change - The primary reason for the performance change is the company's decision to make a large asset impairment provision due to the withdrawal of a drug registration application for a new hepatitis B indication, following the latest review recommendations from the National Medical Products Administration [1] - The company has fully provisioned the development expenses related to this project as asset impairment, but excluding this impact, the net profit for 2025 would remain roughly stable compared to the previous year, indicating continued stable development of the core business [1]